The use of Trk-targeted PET imaging in early clinical stages to assess receptor occupancy, dosing regimen, and NTRK fusion-positive status, or to monitor treatment response in place of sequential tumour biopsy may be both achievable and desirable—as previously done with other molecular targeted TKI therapies [28]. The gene discussed is NTRK1; the disease is neoplasm.